newsfilter
← Latest News
Business Wire·

Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

-- Commenced randomized portion of SELECT-AML-1 trial, with initial data expected in 4Q 2023 -- -- Received FDA Fast Track designation for tamibarotene for the treatment of HR-MDS -- -- On-track to complete enrollment